Mayne Pharma Group Limited

MYX

AU000000MYX0

Pharmaceuticals

Delayed Australian S.E. Other stock markets 08:33:40 2024-07-14 pm EDT			5-day change	1st Jan Change
4.36 ^AUD	-0.91%		+1.87%	-29.11%

Jul. 02	Australian Shares Slide as Central Bank Shows Signs of Possible Rate Hike	MT
Jun. 03	Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland	MT

Mayne Pharma Group Limited announced that it expects to receive $0.35 million in funding.

January 23, 2013 at 11:00 pm EST

Mayne Pharma Group Limited (ASX:MYX) announced that it will raise $346,500 in an equity round of funding on January 24, 2013. The securities will be issued pursuant to Regulation D.

Latest news about Mayne Pharma Group Limited

Australian Shares Slide as Central Bank Shows Signs of Possible Rate Hike	Jul. 02	MT
Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland	Jun. 02	MT
Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack	May. 23	MT
Mayne Pharma Group Limited's Equity Buyback announced on May 10, 2023 has expired with 3,828,461 shares, representing 4.59% for AUD 17.16 million.	May. 23	CI
Mayne Pharma Group Limited's Equity Buyback Plan Extended till November 29, 2024.	May. 23	CI
Mayne Pharma Group Limited announces an Increase in Equity Buyback.	May. 23	CI
Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents	May. 09	MT
Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	Feb. 25	MT
Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024	Feb. 25
Tranche Update on Mayne Pharma Group Limited's Equity Buyback Plan announced on May 10, 2023.	Feb. 25	CI
Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Transcript : Mayne Pharma Group Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Mayne Pharma Group Limited Approves Election of Anne Lockwood	Nov. 29	CI
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	Nov. 29
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mayne Pharma Gets Go-Ahead for Resignation of EY as Auditor	Nov. 03	MT
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	23-10-17
Mayne Pharma Acquires Dermatological Medication	23-09-26	MT
Mayne Pharma Group Limited completed the acquisition of Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC.	23-09-24	CI
Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.	23-09-06	CI
Australian Shares Rebound Ahead of Central Bank Policy Meeting	23-09-04	MT
Mayne Pharma Group Purchasing Global Rights to Topical Treatment RHOFADE	23-09-04	MT

Chart Mayne Pharma Group Limited

Duration

Period

More charts

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Companyâs segments include Womenâs Health, Dermatology, and International. The Womenâs Health segment distributes womenâs health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mayne Pharma Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.4 AUD

Average target price

6.89 AUD

Spread / Average Target

+56.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MAYNE PHARMA GROUP LIMITED	-29.11%	243M
OTSUKA HOLDINGS CO., LTD.	+34.85%	24.51B
SANDOZ GROUP AG	+29.56%	16.85B
CIPLA LIMITED	+21.32%	14.62B
ZYDUS LIFESCIENCES LIMITED	+70.51%	14.16B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.06%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.74%	5.82B
STADA ARZNEIMITTEL	-8.87%	5.73B
GEDEON RICHTER	+10.74%	4.93B

Generic Pharmaceuticals